Form 8-K

8-K — GILEAD SCIENCES, INC.

Accession: 0001104659-26-064518

Filed: 2026-05-20

Period: 2026-05-14

CIK: 0000882095

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2615045d1_8k.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (tm2615045d1_ex1-1.htm)

EX-4.2 — EXHIBIT 4.2 (tm2615045d1_ex4-2.htm)

EX-5.1 — EXHIBIT 5.1 (tm2615045d1_ex5-1.htm)

GRAPHIC (tm2615045d1_ex1-1img001.jpg)

GRAPHIC (tm2615045d1_ex5-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2615045d1_8k.htm · Sequence: 1

false

0000882095

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

The Securities Exchange Act of 1934

DATE

OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 14,

2026

GILEAD SCIENCES, INC.

(Exact name of registrant

as specified in its charter)

Delaware

000-19731

94-3047598

(State or Other Jurisdiction of

Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

333 Lakeside Drive, Foster City, California

(Address of Principal Executive Offices)

94404

(Zip Code)

(650)

574-3000

(Registrant’s Telephone Number, Including

Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on

which registered

Common Stock, par value $0.001 per share

GILD

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934

(§240.12b-2 of this chapter).

Emerging

growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01.

Entry into a Material Definitive Agreement.

Supplemental Indenture

On May 20, 2026, Gilead Sciences,

Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association,

as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental

Indenture (the “Eleventh Supplemental Indenture”) to the Indenture between the Parties, dated as of March 30, 2011 (the

“Base Indenture”). The Eleventh Supplemental Indenture relates to the Company’s issuance of (a) $500,000,000 aggregate

principal amount of the Company’s 4.250% Senior Notes due 2028 (the “2028 Notes”), (b) $1,000,000,000 aggregate

principal amount of the Company’s 4.400% Senior Notes due 2029 (the “2029 Notes”), (c) $1,000,000,000 aggregate

principal amount of the Company’s 4.600% Senior Notes due 2031 (the “2031 Notes”) and (d) $500,000,000 aggregate principal

amount of the Company’s 4.900% Senior Notes due 2034 (the “2034 Notes” and, together with the 2028 Notes, the 2029 Notes

and the 2031 Notes, the “Notes”). The Notes were sold in a public offering pursuant to the Company’s Registration Statement

on Form S-3 (File No. 333-273745).

The 2028 Notes will pay interest

semi-annually at a rate of 4.250% per annum until May 20, 2028. The 2029 Notes will pay interest semi-annually at a rate of 4.400% per

annum until May 20, 2029. The 2031 Notes will pay interest semi-annually at a rate of 4.600% per annum until May 20, 2031. The 2034 Notes

will pay interest semi-annually at a rate of 4.900% per annum until May 20, 2034.

The Company intends to use

the net proceeds from the sale of the Notes for general corporate purposes, which may include funding for acquisitions, investments, strategic

transactions or other business opportunities.

The Base Indenture and the

Eleventh Supplemental Indenture contain certain restrictions, including a limitation that restricts the Company’s ability and ability

of certain of its subsidiaries to create or incur secured indebtedness, enter into sale and leaseback transactions and consolidate, merge

or transfer all or substantially all of the Company’s assets and the assets of its subsidiaries, and also requires the Company to

offer to repurchase the Notes upon certain change of control events.

The Company may redeem some

or all of the Notes at any time and from time to time at the applicable redemption prices described in the form of such notes.

For a complete description

of the terms and conditions of the Base Indenture, please refer to the Base Indenture, filed as Exhibit 4.1 to the Company’s

Current Report on Form 8-K, filed with the Commission on April 1, 2011, and incorporated herein by reference. For a complete description

of the terms and conditions of the Eleventh Supplemental Indenture and the Notes, please refer to the Eleventh Supplemental Indenture

and the forms of each series of Notes, each of which is incorporated herein by reference and attached to this Current Report on Form

8-K as Exhibits 4.2, 4.3, 4.4, 4.5 and 4.6, respectively.

Item 2.03. Creation of a Direct

Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The

information set forth in Item 1.01 is incorporated herein by reference.

Item 8.01.

Other Information.

Underwriting Agreement

On May 14, 2026, the Company

entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BofA Securities, Inc. and

Citigroup Global Markets Inc., as representatives of the several underwriters listed in Schedule 1 thereto, relating to the issuance and

sale by the Company of the Notes.

The description of the Underwriting

Agreement contained herein is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this

Current Report on Form 8-K and is incorporated herein by reference.

The above-mentioned offering

was made pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-273745). An opinion of counsel

for the Company is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

1.1

Underwriting Agreement, dated May 14, 2026, among the Company and Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc., as representatives of the several underwriters listed in Schedule 1 thereto

4.1

Indenture, dated as of March 30, 2011, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the Commission on April 1, 2011)

4.2

Eleventh Supplemental Indenture, dated as of May 20, 2026, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee

4.3

Form of 2028 Note (included in Exhibit 4.2 above)

4.4

Form of 2029 Note (included in Exhibit 4.2 above)

4.5

Form of 2031 Note (included in Exhibit 4.2 above)

4.6

Form of 2034 Note (included in Exhibit 4.2 above)

5.1

Opinion of Sidley Austin LLP regarding the validity of the Notes

23.1

Consent of Sidley Austin LLP (included as part of Exhibit 5.1)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.

By:

/s/

Andrew D. Dickinson

Name:

Andrew D. Dickinson

Title:

Executive Vice President and Chief Financial

Officer

Dated: May 20, 2026

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: tm2615045d1_ex1-1.htm · Sequence: 2

Exhibit 1.1

GILEAD SCIENCES, INC.

Underwriting Agreement

May 14, 2026

Barclays Capital Inc.

BofA Securities, Inc.

Citigroup Global Markets Inc.

as Representatives of the several Underwriters

listed in Schedule 1 hereof

c/o Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

c/o BofA Securities, Inc.

One Bryant Park

New York, New York 10036

c/o Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

Ladies and Gentlemen:

Gilead Sciences, Inc.,

a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule

1 hereto (the “Underwriters”), for whom Barclays Capital Inc. (“Barclays”), BofA

Securities, Inc. (“BofA”) and Citigroup Global Markets Inc. (“Citi”) are acting

as representatives (the “Representatives”), $500,000,000 principal amount of its 4.250% Senior Notes due 2028

(the “2028 Notes”), $1,000,000,000 principal amount of its 4.400% Senior Notes due 2029 (the “2029

Notes”), $1,000,000,000 principal amount of its 4.600% Senior Notes due 2031 (the “2031 Notes”)

and $500,000,000 principal amount of its 4.900% Senior Notes due 2034 (the “2034 Notes” and, together with the

2028 Notes, the 2029 Notes and the 2031 Notes, the “Securities”).

The Securities will be issued

pursuant to an Indenture dated as of March 30, 2011 (the “Base Indenture”) between the Company and Computershare

Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee”), as

supplemented by a supplemental indenture to be dated as of May 20, 2026 (together with the Base Indenture, the “Indenture”).

The Company hereby confirms

its agreement with the several Underwriters concerning the purchase and sale of the Securities, as follows:

1.              Registration

Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”)

under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities

Act”), a registration statement on Form S-3 (File No. 333-273745), including a prospectus, relating to the Securities.

Such registration statement, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act

to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”), is

referred to herein as the “Registration Statement”; and as used herein, the term “Preliminary Prospectus”

means each prospectus included in such registration statement (and any amendments thereto) before it became effective, any prospectus

filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement

at the time of its effectiveness that omits Rule 430 Information, and the term “Prospectus” means the prospectus

in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection

with confirmation of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under

the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term “Registration

Statement” shall be deemed to include such Rule 462 Registration Statement. Any reference in this Agreement to the Registration

Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference

therein pursuant to Item 12 of Form S-3 under the Securities Act, as of the effective date of the Registration Statement or the date

of such Preliminary Prospectus or the Prospectus, as the case may be and any reference to “amend”, “amendment”

or “supplement” with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to

refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and

regulations of the Commission thereunder (collectively, the “Exchange Act”) that are deemed to be incorporated

by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement

and the Prospectus.

At or prior to 4:00 P.M.,

New York City time, on the date hereof (the “Time of Sale”), the Company had prepared the following information

(collectively, the “Time of Sale Information”): a Preliminary Prospectus dated May 14, 2026, and each “free-writing

prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto as constituting part

of the Time of Sale Information.

2.              Purchase

of the Securities by the Underwriters.

(a)            The

Company agrees to issue and sell the Securities to the several Underwriters as provided in this Agreement, and each Underwriter, on the

basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally

and not jointly, to purchase from the Company the respective principal amount of Securities set forth opposite such Underwriter’s

name in Schedule 1 hereto at a price equal to 99.758% of the aggregate principal amount of the 2028 Notes, 99.731% of the aggregate

principal amount of the 2029 Notes, 99.646% of the aggregate principal amount of the 2031 Notes and 99.567% of the aggregate principal

amount of the 2034 Notes, in each case, plus accrued interest, if any, from May 20, 2026 to the Closing Date (as defined below).

The Company will not be obligated to deliver any of the Securities except upon payment for all the Securities to be purchased as provided

herein.

(b)            The

Company understands that the Underwriters intend to make a public offering of the Securities as soon after the effectiveness of this Agreement

as in the judgment of the Representatives is advisable, and initially to offer the Securities on the terms set forth in the Prospectus.

The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter

and that any such affiliate may offer and sell Securities purchased by it to or through any Underwriter.

for and delivery of the Securities will be made at the offices of Latham & Watkins LLP, 1271 Avenue of the Americas, New York,

NY 10020 at 10:00 A.M., New York City time, on May 20, 2026, or at such other time or place on the same or such other date, not later

than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such payment

for the Securities is referred to herein as the “Closing Date”.

(d)            Payment

for the Securities shall be made by wire transfer in immediately available funds to the account(s) specified by the Company to the

Representatives against delivery to the nominee of The Depository Trust Company, for the respective accounts of the several Underwriters

of one or more global notes representing the Securities (collectively, the “Global Note”), with any transfer

or other similar taxes payable in connection with the sale of such Securities duly paid by the Company. The Global Note will be made available

for inspection by the Representatives at the offices of Latham & Watkins LLP set forth above not later than 1:00 P.M., New York

City time, on the business day prior to the Closing Date.

(e)            The

Company acknowledges and agrees that the Underwriters are acting solely in the capacity of an arm’s-length contractual counterparty

to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the

offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the

Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or

regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible

for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no

responsibility or liability to the Company with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated

hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on

behalf of the Company. The Company agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services

of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading

thereto.

3.              Representations

and Warranties of the Company. The Company represents and warrants to each Underwriter that:

(a)            Preliminary

Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary

Prospectus, at the time of filing thereof, complied in all material respects with the Securities Act and did not contain any untrue statement

of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein,

in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation

and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter

furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it

being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such

in Section 7(b) hereof.

(b)            Time

of Sale Information. The Time of Sale Information, at the Time of Sale, did not contain any untrue statement of a material fact or

omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were

made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions

made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter

through the Representatives expressly for use in such Time of Sale Information, it being understood and agreed that the only such information

furnished by any Underwriter consists of the information described as such in Section 7(b) hereof. No statement of material

fact included in the Prospectus has been omitted from the Time of Sale Information and no statement of material fact included in the Time

of Sale Information that is required to be included in the Prospectus has been omitted therefrom.

Free Writing Prospectus. The Company (including its agents and representatives, other than the Underwriters in their capacity as such)

has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any

“written communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation

of an offer to buy the Securities (each such communication by the Company or its agents and representatives (other than a communication

referred to in clauses (i), (ii), (iii) and (iv) below) an “Issuer Free Writing Prospectus”) other

than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134

under the Securities Act, (ii) the Preliminary Prospectus, (iii) the Prospectus, (iv) the Registration Statement, (v) the

documents listed on Annex A hereto, including the term sheets substantially in the form of Annex B hereto, each of which constitutes part

of the Time of Sale Information and (vi) any electronic road show and any other written communications approved in writing in advance

by the Representatives. Each such Issuer Free Writing Prospectus complied in all material respects with the Securities Act, has been or

will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby)

and, when taken together with the Preliminary Prospectus filed prior to the first use of such Issuer Free Writing Prospectus, did not,

and at the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order

to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the

Company makes no representation and warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus

in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter

through the Representatives expressly for use in any Issuer Free Writing Prospectus, it being understood and agreed that the only such

information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(d)            Registration

Statement and Prospectus. The Registration Statement is an “automatic shelf registration statement” as defined under Rule 405

of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of

objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under

the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been issued

by the Commission and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related

to the offering of the Securities has been initiated or threatened by the Commission; as of the applicable effective date of the Registration

Statement and any amendment thereto, the Registration Statement complied and will comply in all material respects with the Securities

Act and the Trust Indenture Act of 1939, as amended, and the rules and regulations of the Commission thereunder (collectively, the

“Trust Indenture Act”), and did not and will not contain any untrue statement of a material fact or omit to

state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the

date of the Prospectus and any amendment or supplement thereto and as of the Closing Date, the Prospectus will not contain any untrue

statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements

therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation

and warranty with respect to (i) that part of the Registration Statement that constitutes the Statement of Eligibility and Qualification

(Form T-1) of the Trustee under the Trust Indenture Act or (ii) any statements or omissions made in reliance upon and in conformity

with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly

for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that

the only such information furnished by any Underwriter consists of the information described as such in Section 7(b) hereof.

(e)            Incorporated

Documents. The documents incorporated by reference in the Registration Statement, the Prospectus and the Time of Sale Information,

when they became effective or were filed with the Commission, as the case may be, conformed in all material respects with the requirements

of the Exchange Act and none of such documents contained any untrue statement of a material fact or omitted to state a material fact required

to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Time of Sale Information,

when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects with

the requirements of the Securities Act or the Exchange Act, as applicable, and will not contain any untrue statement of a material fact

or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances

under which they were made, not misleading.

(f)             Financial

Statements. The financial statements and the related notes thereto of the Company and its consolidated subsidiaries included or incorporated

by reference in the Registration Statement, the Time of Sale Information and the Prospectus comply in all material respects with the applicable

requirements of the Securities Act and the Exchange Act, as applicable, and present fairly, in all material respects, the financial position

of the Company and its consolidated subsidiaries, as of the dates indicated and the results of their operations and the changes in their

cash flows for the periods specified; such financial statements have been prepared in conformity with U.S. generally accepted accounting

principles (“GAAP”) applied on a consistent basis throughout the periods covered thereby. The interactive data

in eXtensible Business Reporting Language of the Company and its consolidated subsidiaries incorporated by reference in the Registration

Statement, the Time of Sale Information and the Prospectus fairly presents the information called for in all material respects and has

been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(g)            No

Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by reference

in the Registration Statement, the Time of Sale Information and the Prospectus, except as otherwise stated therein (i) there has

been no material adverse change in the business, financial condition, prospects or in the earnings of the Company and its subsidiaries

considered as one enterprise, (ii) there have been no transactions entered into by the Company or any of its subsidiaries, other

than those in the ordinary course of business, which are material with respect to the Company and its subsidiaries considered as one enterprise

and (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital

stock not described in the Registration Statement, the Time of Sale Information and the Prospectus.

(h)            Organization

and Good Standing. Each of the Company, Kite Pharma, Inc., a Delaware corporation (“Kite”), Gilead

Sciences Ireland UC, an unlimited company organized under the laws of the Republic of Ireland (“Gilead Ireland”)

and Immunomedics, Inc., a Delaware corporation (“Immunomedics” and, together with Kite and Gilead Ireland,

the “Significant Subsidiaries”), has been duly incorporated and is validly existing and in good standing under

the laws of the jurisdiction in which it is incorporated, chartered or organized, with the corporate or company power and authority to

own or lease, as the case may be, and to operate its properties and conduct its business as described in the Registration Statement, the

Time of Sale Information and the Prospectus and is duly qualified to do business as a foreign corporation or organization and is in good

standing under the laws of each jurisdiction which requires such qualification, except, in each case, where the failure so to qualify

or to be in good standing would not have a Material Adverse Effect (as defined below). The Significant Subsidiaries are the only significant

subsidiaries (as defined in Rule 1-02 of Regulation S-X under the Exchange Act) of the Company. As used herein, “Material

Adverse Effect” means a material adverse effect on the business or financial condition of the Company and its subsidiaries,

considered as one enterprise.

(i)             Capitalization.

The capitalization of the Company as of March 31, 2026, is as set forth in the Time of Sale Information and the Prospectus

in the column entitled “Actual” under the caption “Capitalization.” The outstanding shares of capital stock of

the Company have been duly and validly authorized and issued and are fully paid and nonassessable; none of the outstanding shares of capital

stock of the Company was issued in violation of the preemptive or similar rights of any security holder of the Company. Except as described

in the Registration Statement, the Time of Sale Information and the Prospectus, there are no outstanding rights (including, without limitation,

pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock

or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement

of any kind relating to the issuance of any capital stock or other equity interest, as applicable, of the Company or any such subsidiary,

any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in

all material respects to the description thereof contained in the Registration Statement, the Time of Sale Information and the Prospectus.

There are no persons with registration rights or other similar rights to have any securities included in any registration statement filed

pursuant to a registration agreement or in any offering made pursuant to such registration statement. All the issued and outstanding shares

of capital stock or other equity interest, as applicable, of each Significant Subsidiary have been duly and validly authorized and issued

and are fully paid and nonassessable, and, except as may be otherwise set forth in the Registration Statement, the Time of Sale Information

and the Prospectus, all outstanding shares of capital stock or other equity interest, as applicable, of the Significant Subsidiaries are

owned by the Company either directly or through a wholly-owned subsidiary free and clear of any security interest, mortgage, pledge, lien,

encumbrance, claim or equity; none of the outstanding shares of capital stock or other equity interest, as applicable, of any Significant

Subsidiary was issued in violation of the preemptive or similar rights of any securityholder of any Significant Subsidiary.

(j)             The

Indenture. The Indenture has been duly authorized by the Company and upon effectiveness of the Registration Statement was or will

have been duly qualified under the Trust Indenture Act, and when duly executed and delivered by the Company and, assuming the due authorization,

execution and delivery of the Indenture by the Trustee, will be a valid and binding agreement of the Company enforceable against the Company

in accordance with its terms, except (i) to the extent that a waiver of rights under any usury laws may be unenforceable and as the

enforceability thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium or other similar laws now or hereafter

in effect relating to or affecting the enforcement of creditors’ rights and remedies generally and (ii) as rights of acceleration

and the availability of equitable remedies may be limited by equitable principles of general applicability, whether or not enforcement

is sought at law or in equity.

(k)            Underwriting

Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(l)             The

Securities. The Securities have been duly authorized by the Company, and, at the Closing Date, will have been duly executed by the

Company and, when authenticated, issued and delivered in the manner provided for in the Indenture and delivered against payment of the

purchase price as provided in this Agreement, will be the valid and binding obligations of the Company, enforceable against the Company

in accordance with their terms, except (i) to the extent that a waiver of rights under any usury laws may be unenforceable and as

the enforceability thereof may be limited by bankruptcy, insolvency, fraudulent conveyance, moratorium or other similar laws now or hereafter

in effect relating to or affecting the enforcement of creditors’ rights and remedies generally and (ii) as rights of acceleration

and the availability of equitable remedies may be limited by equitable principles of general applicability, whether or not enforcement

is sought at law or in equity. At the Closing Date, the Securities will be in the form contemplated by, and will be entitled to the benefits

of, the Indenture.

(m)           Descriptions

of the Transaction Documents. The Securities and the Indenture will conform in all material respects to the respective statements

relating thereto contained in the Registration Statement, the Time of Sale Information and the Prospectus.

(n)            No

Violation and No Conflicts. The Company is not in violation of its Restated Certificate of Incorporation, as amended as of the date

of this Agreement (the “Certificate of Incorporation”), or its Amended and Restated Bylaws, as amended as of

the date of this Agreement (the “Bylaws”). No Significant Subsidiary is in violation of its certificate of incorporation,

by-laws or equivalent, each as amended as of the date of this Agreement. Neither the Company nor any Significant Subsidiary is in default

in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed

of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a

party or by which it or any of them may be bound, or to which any of the property or assets of the Company or any of its subsidiaries

is subject, except for such defaults that would not result in a Material Adverse Effect. The execution, delivery and performance by the

Company of its obligations under this Agreement, the Indenture and the Securities will not contravene any provision of (i) the Certificate

of Incorporation or the Bylaws, (ii) any agreement or other instrument binding upon the Company or its business or assets that

is material to the financial condition of the Company and its subsidiaries, considered as one enterprise, (iii) applicable law or (iv) any

judgment, order, decree of any governmental body, agency or court having jurisdiction over the Company or its business or assets.

(o)            No

Consents Required. No consent, approval, authorization or order of or qualification with any governmental body or agency is required

for the performance by the Company of its obligations under this Agreement, the Indenture or in connection with the offering, issuance

and sale of the Securities, except (A) such as have been already obtained or will have been obtained prior to the Closing Date and

(B) as may be required under the Securities Act or the Trust Indenture Act, in each case with respect to transactions contemplated

by the Indenture.

(p)            Legal

Proceedings. Except as described in the Registration Statement, the Time of Sale Information and the Prospectus, there is no action,

suit, proceeding, inquiry or investigation before or brought by any court or governmental agency or body, domestic or foreign, now pending,

or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries which might reasonably be

expected to result in a Material Adverse Effect or which might reasonably be expected to materially and adversely affect the properties

or assets of the Company or any of its subsidiaries or the consummation of the transactions contemplated by this Agreement or the performance

by the Company of its obligations hereunder. The aggregate of all pending legal or governmental proceedings to which the Company or any

of its subsidiaries is a party or of which any of their respective property or assets is the subject which are not described in the Registration

Statement, the Time of Sale Information and the Prospectus, including ordinary routine litigation incidental to the business, could not

reasonably be expected to result in a Material Adverse Effect.

(q)            Independent

Accountants. Ernst & Young LLP, independent registered public accounting firm, which has audited certain consolidated

financial statements of the Company and its consolidated subsidiaries to be incorporated by reference in the Prospectus, are independent

registered public accountants with respect to the Company and its subsidiaries within the applicable rules and regulations adopted

by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.

(r)             Title

to Intellectual Property. The Company and the Significant Subsidiaries own or possess, or can acquire on reasonable terms, adequate

patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary

or confidential information, systems or procedures), trademarks, service marks and trade names (collectively, the “Intellectual

Property”) which in each case are material to the financial condition of the Company and its subsidiaries considered as

one enterprise and, except as described in the Registration Statement, the Time of Sale Information and the Prospectus, neither the Company

nor any Significant Subsidiary has received any notice of any infringement of or conflict with asserted rights of others with respect

to any Intellectual Property, which infringement or conflict, individually or in the aggregate, could reasonably be expected to result

in a Material Adverse Effect.

(s)            Investment

Company Act. The Company is not and, after giving effect to the offering and sale of the Securities and the application of the proceeds

thereof as described in the Registration Statement, the Time of Sale Information and the Prospectus, will not be an “investment

company” or an entity “controlled” by an “investment company” as such terms are defined in the Investment

Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment

Company Act”).

(t)             Taxes.

The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid

or filed through the date hereof, except for such failures to pay or to file as would not, individually or in the aggregate, reasonably

be expected to have a Material Adverse Effect; and except as otherwise disclosed in the Registration Statement, the Time of Sale Information

and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any

of its subsidiaries or any of their respective properties or assets, except for such tax deficiencies as would not, individually or in

the aggregate, have a Material Adverse Effect.

(u)            Licenses

and Permits. The Company has all necessary consents, authorizations, approvals, orders, certificates and permits of and from (collectively,

the “Governmental Permits”), and has made all declarations and filings with, all federal, state, local and other

governmental authorities, all self-regulatory organizations and all courts and other tribunals, to own, lease, license and use its properties

and assets and to conduct its business in the manner described in the Registration Statement, the Time of Sale Information and the Prospectus,

except to the extent that the failure to obtain or file would not have a Material Adverse Effect; and the Company has not received any

notice of proceedings relating to the revocation or modification of any such Governmental Permits which, individually or in the aggregate,

could reasonably be expected to result in a Material Adverse Effect.

(v)            Compliance

With Environmental Laws. Except as described in the Registration Statement, the Time of Sale Information and the Prospectus and except

as would not, individually or in the aggregate, result in a Material Adverse Effect, (i) neither the Company nor any of its subsidiaries

is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common

law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment,

relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater,

land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened

release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively,

the “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal,

transport or handling of Hazardous Materials (collectively, the “Environmental Laws”), (ii) the Company

and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance

with their requirements, (iii) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands,

demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law

against the Company or any of its subsidiaries and (iv) there are no events or circumstances that might reasonably be expected to

form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or

agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.

(w)           Hazardous

Substances. Neither the Company nor any of its subsidiaries is in violation of any federal or state law or regulation relating to

occupational safety and health or to the storage, handling and transportation of hazardous or toxic materials; the Company and each of

its subsidiaries have received all permits, licenses or other approvals required of them under applicable federal and state occupational

safety and health laws and Environmental Laws and regulations to conduct their respective businesses, and the Company and each of its

subsidiaries is in compliance with all terms and conditions of any such permit, license or approval, except for any such violation of

law or regulation, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions

of such permits, licenses or approvals that would not, singly or in the aggregate, result in a Material Adverse Effect, except as described

in or contemplated by the Registration Statement, the Time of Sale Information and the Prospectus.

(x)            Compliance

With ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security

Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group”

(defined as any trade or business which is a member of a controlled group of corporations within the meaning of Section 414 of the

Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”)

has been maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,

including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA

or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative

exemption and excluding transactions that, individually or in the aggregate, would not reasonably be expected to result in a Material

Adverse Effect; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302

of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code, whether or not waived, has occurred

or is reasonably expected to occur; (iv) the fair market value of the assets of each Plan exceeds the present value of all benefits

accrued under such Plan (determined based on those assumptions used to fund such Plan) except to the extent that any such accumulated

funding deficiency could not reasonably be expected to result in a Material Adverse Effect with respect to the Company; (v) no “reportable

event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur that, individually

or in the aggregate, could reasonably be expected to result in a Material Adverse Effect; and (vi) neither the Company nor any member

of its Controlled Group has incurred, nor reasonably expects to incur, any material liability under Title IV of ERISA (other than contributions

to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including a “multiemployer

plan”, within the meaning of Section 4001(a)(3) of ERISA).

(y)            Disclosure

Controls. The Company maintains an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of

the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in reports that it files or submits

under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and

forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s

management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness

of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

(z)            Accounting

Controls. The Company and its subsidiaries, taken as a whole, maintain a system of internal accounting controls sufficient to provide

reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization;

(B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain

accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific

authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate

action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated

by reference in the Registration Statement, the Time of Sale Information and the Prospectus fairly presents the information called for

in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except

as disclosed in the Registration Statement, the Time of Sale Information and the Prospectus, there are no material weaknesses in the Company’s

internal controls.

(aa)          Insurance.

The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks

and in such amounts as are reasonable and consistent with sound business practice.

(bb)          Compliance

with Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance

with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as

amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules,

regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering

Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator

involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company,

threatened.

(cc)          Compliance

with Sanctions. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee

or affiliate of the Company or any of its subsidiaries is currently the subject or target of any sanctions administered or enforced by

the government of the United States, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets

Control, the United Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority

(collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that

is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder,

or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for

the purpose of financing the activities of any person currently subject to any Sanctions.

(dd)          No

Restrictions on Subsidiaries. No Significant Subsidiary is currently prohibited, directly or indirectly, under any agreement or other

instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such

subsidiary’s capital stock or other equity interest, as applicable, from repaying to the Company any loans or advances to such subsidiary

from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the

Company, except as may be described in or contemplated by the Registration Statement, the Time of Sale Information and the Prospectus

and except as would not result in a Material Adverse Effect.

(ee)          No

Registration Rights. No person has the right to require the Company or any of its subsidiaries to register any securities for sale

under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities.

(ff)           No

Stabilization. The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause

or result in any stabilization or manipulation of the price of the Securities.

(gg)         Status

Under the Securities Act. The Company is not an ineligible issuer and is a well-known seasoned issuer, in each case as defined under

the Securities Act, in each case at the times specified in the Securities Act in connection with the offering of the Securities.

(hh)         Cybersecurity.

(A) To the Company’s knowledge, there has been no security breach or incident, unauthorized access or disclosure, or other

compromise of or relating to the Company or its subsidiaries’ information technology and computer systems, networks, hardware, software,

data and databases (including, as applicable, the data and information of their respective customers, employees, suppliers, vendors and

any third party data maintained, processed or stored by the Company and its subsidiaries, and any such data processed or stored by third

parties on behalf of the Company and its subsidiaries), equipment or technology (collectively, “IT Systems and Data”),

except in each case as would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect; and (B) the

Company and its subsidiaries have implemented appropriate controls, policies, procedures, and technological safeguards to maintain and

protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent in all material

respects with industry standards and practices and applicable regulatory standards. The Company and its subsidiaries are presently in

material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator

or governmental or regulatory authority relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems

and Data from unauthorized use, access, misappropriation or modification.

4.              Further

Agreements of the Company. The Company covenants and agrees with each Underwriter that:

(a)            Required

Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and

Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus (including the term sheets in the

form of Annex B hereto) to the extent required by Rule 433 under the Securities Act and will file promptly all reports and

any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a),

13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is

required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer

Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City

time, on the second business day succeeding the date of this Agreement in such quantities as the Representatives may reasonably request.

The Company will pay the registration fees for this offering within the time period required by Rule 456(b)(1)(i) under the

Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date.

(b)            Delivery

of Copies. The Company will deliver, without charge, (i) to the Representatives, two signed copies of the Registration Statement

as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith; and (ii) to each

Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without any exhibits)

and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and

supplements thereto and documents incorporated by reference therein) and each Issuer Free Writing Prospectus as the Representatives may

reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of time after the

first date of the public offering of the Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Securities

is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales

of the Securities by any Underwriter or dealer.

or Supplements; Issuer Free Writing Prospectuses. Before making, preparing, using, authorizing, approving, referring to or filing

any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or the Prospectus, whether

before or after the time that the Registration Statement becomes effective the Company will furnish to the Representatives and counsel

for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare,

use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to

which the Representatives reasonably object.

(d)            Notice

to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing, (i) when the

Registration Statement has become effective; (ii) when any amendment to the Registration Statement has been filed or becomes effective;

(iii) when any supplement to the Prospectus or any amendment to the Prospectus or any Issuer Free Writing Prospectus has been filed;

(iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus

or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any

additional information; (v) of the issuance by the Commission of any order suspending the effectiveness of the Registration Statement

or preventing or suspending the use of any Preliminary Prospectus or the Prospectus or the initiation or threatening of any proceeding

for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event within the Prospectus

Delivery Period as a result of which the Prospectus, the Time of Sale Information or any Issuer Free Writing Prospectus as then amended

or supplemented would include any untrue statement of a material fact or omit to state a material fact required to be stated therein or

necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Time of Sale Information

or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; (vii) of the receipt by the Company of any

notice of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under

the Securities Act; and (viii) of the receipt by the Company of any notice with respect to any suspension of the qualification of

the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company

will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement,

preventing or suspending the use of any Preliminary Prospectus or the Prospectus or suspending any such qualification of the Securities

and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof.

(e)            Time

of Sale Information. If at any time prior to the Closing Date (i) any event shall occur or condition shall exist as a result

of which the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or omit to

state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,

not misleading or (ii) it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company will promptly

notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent

required) and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements to

the Time of Sale Information as may be necessary so that the statements in the Time of Sale Information as so amended or supplemented

will not, in the light of the circumstances, be misleading or so that the Time of Sale Information will comply with law.

(f)             Ongoing

Compliance. If during the Prospectus Delivery Period (i) any event shall occur or condition shall exist as a result of which

the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact

required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances existing when the

Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with

law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with

the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate, such amendments or supplements

to the Prospectus as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of

the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law.

(g)            Blue

Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions

as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of

the Securities; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or

as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general

consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not

otherwise so subject.

(h)            Earning

Statement. The Company will make generally available to its security holders and the Representatives as soon as practicable an earning

statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated

thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective

date” (as defined in Rule 158) of the Registration Statement.

(i)             Clear

Market. During the period from the date hereof through and including the business day following the Closing Date, the Company will

not, without the prior written consent of the Representatives, directly or indirectly, offer, sell, contract to sell or otherwise dispose

of any debt securities issued or guaranteed by the Company and having a tenor of more than one year.

(j)             Use

of Proceeds. The Company will apply the net proceeds from the sale of the Securities as described in the Registration Statement, the

Time of Sale Information and the Prospectus under the heading “Use of Proceeds”.

(k)            No

Stabilization. The Company will not take, directly or indirectly, any action designed to or that could reasonably be expected to cause

or result in any stabilization or manipulation of the price of the Securities.

(l)             Record

Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing

Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.

5.              Certain

Agreements of the Underwriters. Each Underwriter hereby represents and agrees that it has not used, authorized use of, referred to,

or participated in the planning of use of, and will not use, authorize use of, refer to, or participate in the planning for use of, any

“free writing prospectus”, as defined in Rule 405 under the Securities Act (which term includes use of any written information

furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued

by the Company) other than (i) a free writing prospectus that, solely as a result of use by such Underwriter, would not trigger an

obligation to file such free writing prospectus with the Commission pursuant to Rule 433, (ii) any Issuer Free Writing Prospectus

listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road

show), or (iii) any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing. Notwithstanding

the foregoing, the Underwriters may use the term sheets substantially in the form of Annex B hereto without the consent of the

Company.

6.              Conditions

of Underwriters’ Obligations. The obligation of each Underwriter to purchase Securities on the Closing Date as provided herein

is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions:

(a)            Registration

Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding

for such purpose, pursuant to Rule 401(g)(2) or pursuant to Section 8A under the Securities Act shall be pending before

or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission

under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities

Act) and in accordance with Section 4(a) hereof; and all requests by the Commission for additional information shall have been

complied with to the reasonable satisfaction of the Representatives.

(b)            Representations

and Warranties. The representations and warranties of the Company contained herein shall be true and correct on the date hereof and

on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this

Agreement shall be true and correct on and as of the Closing Date.

Downgrade. Subsequent to the earlier of (A) the Time of Sale and (B) the execution and delivery of this Agreement, (i) no

downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock of or guaranteed

by the Company or any of its subsidiaries by any “nationally recognized statistical rating organization”, as such term is

defined by the Commission for purposes of Section 3(a)(62) under the Exchange Act and (ii) no such organization shall have publicly

announced that it has under surveillance or review, or has changed its outlook with respect to, its rating of the Securities or of any

other debt securities or preferred stock of or guaranteed by the Company or any of its subsidiaries (other than an announcement with positive

implications of a possible upgrading).

(d)            No

Material Adverse Change. No event or condition of a type described in Section 3(g) hereof shall have occurred or shall exist,

which event or condition is not described in the Time of Sale Information (excluding any amendment or supplement thereto) and the Prospectus

(excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable

or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement,

the Time of Sale Information and the Prospectus.

(e)            Officer’s

Certificate. The Representatives shall have received on and as of the Closing Date a certificate of the chief financial officer of

the Company or another senior executive officer of the Company who is satisfactory to the Representatives (i) confirming that such

officer has carefully reviewed the Registration Statement, the Time of Sale Information and the Prospectus and, to the best knowledge

of such officer, the representations set forth in Sections 3(a) and 3(b) hereof are true and correct, (ii) confirming that

the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with

all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date and (iii) to

the effect set forth in paragraphs (a), (c) and (d) above.

(f)             Comfort

Letters. On the date of this Agreement and on the Closing Date, Ernst & Young LLP shall have furnished to the Representatives

and the board of directors of the Company, at the request of the Company, letters, dated the respective dates of delivery thereof and

addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information

of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements

and certain financial information contained or incorporated by reference in the Registration Statement, the Time of Sale Information and

the Prospectus; provided, that the letter delivered on the Closing Date shall use a “cut-off” date no more than three

business days prior to the Closing Date.

(g)            Opinion

and 10b-5 Statement of Counsel for the Company. Sidley Austin LLP, counsel for the Company, shall have furnished to the Representatives,

at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date and addressed to the Underwriters, in

form and substance reasonably satisfactory to the Representatives.

(h)            Opinion

of General Counsel for the Company. The General Counsel of the Company shall have furnished to the Representatives, at the request

of the Company, her written opinion, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory

to the Representatives.

(i)             Opinion

and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall have received on and as of the Closing Date an opinion

and 10b-5 statement of Latham & Watkins LLP, counsel for the Underwriters, with respect to such matters as the Representatives

may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them

to pass upon such matters.

(j)              No

Legal Impediment to Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted

or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance

or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of

the Closing Date, prevent the issuance or sale of the Securities.

(k)              Good

Standing. The Representatives shall have received on and as of the Closing Date satisfactory evidence of the good standing of the

Company and each Significant Subsidiary and the Company’s good standing as a foreign corporation in California, in each case in

writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions.

All opinions, letters, certificates

and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they

are in form and substance reasonably satisfactory to counsel for the Underwriters.

In addition, the several obligations

of the Underwriters to purchase the Securities hereunder are subject to the delivery to the Underwriters on the Closing Date, if any,

of such other documents as the Underwriters may reasonably request with respect to: (1) the good standing of the Company; and

(2) the due authorization, execution, authentication and issuance of the Securities to be sold on the Closing Date and matters

related thereto, respectively.

7.              Indemnification

and Contribution.

(a)            Indemnification

of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and

each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the

Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees

and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred),

joint or several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained

in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein

or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, or (ii) any

untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto),

any Issuer Free Writing Prospectus or any Time of Sale Information, or caused by any omission or alleged omission to state therein a material

fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each

case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or

alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished

to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that

the only such information furnished by any Underwriter consists of the information described as such in subsection (b) below.

(b)            Indemnification

of the Company. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its

officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above,

but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission

or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished

to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus

(or any amendment or supplement thereto), any Issuer Free Writing Prospectus or any Time of Sale Information, it being understood and

agreed upon that the only such information furnished by any Underwriter consists of the information contained in the eighth paragraph

of the Preliminary Prospectus and the Prospectus under the heading “Underwriting.”

and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be

brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above,

such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may

be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying

Person shall not relieve it from any liability that it may have under paragraph (a) or (b) above except to the extent that it

has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further,

that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise

than under paragraph (a) or (b) above. If any such proceeding shall be brought or asserted against an Indemnified Person and

it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified

Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified

Person in such proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding,

any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense

of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary;

(ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person;

(iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different

from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any

impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel

would be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person

shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more

than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid

or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control

persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors,

its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company.

The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled

with such consent or if there be a final judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person

from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time

an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel

as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written

consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request, and (ii) the

Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement.

No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened

proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder

by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and

substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding

and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified

Person.

(d)            Contribution.

If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person or insufficient

in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu

of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result

of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received

by the Company, on the one hand, and the Underwriters, on the other, from the offering of the Securities or (ii) if the allocation

provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative

benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters, on the other,

in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant

equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, shall be

deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale

of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case

as set forth in the table on the cover the Prospectus, bear to the aggregate offering price of the Securities. The relative fault of the

Company, on the one hand, and the Underwriters, on the other, shall be determined by reference to, among other things, whether the untrue

or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied

by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct

or prevent such statement or omission.

(e)            Limitation

on Liability. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 7

were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method

of allocation that does not take account of the equitable considerations referred to in paragraph (d) above. The amount paid or payable

by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be deemed

to include, subject to the limitations set forth above, any reasonable legal or other expenses incurred by such Indemnified Person in

connection with any such action or claim. Notwithstanding the provisions of this Section 7, in no event shall an Underwriter be required

to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter

with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to

pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation

(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty

of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 7 are several in

proportion to their respective purchase obligations hereunder and not joint.

(f)             Non-Exclusive

Remedies. The remedies provided for in this Section 7 are not exclusive and shall not limit any rights or remedies which may

otherwise be available to any Indemnified Person at law or in equity.

8.              Effectiveness

of Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

9.              Termination.

This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and

delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on

or by any of the New York Stock Exchange or the Nasdaq Global Select Market; (ii) trading of any securities issued or guaranteed

by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial

banking activities shall have been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak

or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States,

that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering,

sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of Sale Information and the

Prospectus.

10.            Defaulting

Underwriter.

(a)            If,

on the Closing Date, any Underwriter defaults on its obligation to purchase the Securities that it has agreed to purchase hereunder, the

non-defaulting Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company

on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters

do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of 36 hours within which to

procure other persons satisfactory to the non-defaulting Underwriters to purchase such Securities on such terms. If other persons become

obligated or agree to purchase the Securities of a defaulting Underwriter, either the non-defaulting Underwriters or the Company may postpone

the Closing Date for up to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel

for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the

Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such

changes. As used in this Agreement, the term “Underwriter” includes, for all purposes of this Agreement unless the context

otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 10, purchases Securities that a defaulting

Underwriter agreed but failed to purchase.

(b)            If,

after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting

Underwriters and the Company as provided in paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased

does not exceed one-eleventh of the aggregate principal amount of all the Securities, then the Company shall have the right to require

each non-defaulting Underwriter to purchase the principal amount of Securities that such Underwriter agreed to purchase hereunder plus

such Underwriter’s pro rata share (based on the principal amount of Securities that such Underwriter agreed to purchase hereunder)

of the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made.

after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the non-defaulting

Underwriters and the Company as provided in paragraph (a) above, the aggregate principal amount of such Securities that remains unpurchased

exceeds one-eleventh of the aggregate principal amount of all the Securities, or if the Company shall not exercise the right described

in paragraph (b) above, then this Agreement shall terminate without liability on the part of the non-defaulting Underwriters. Any

termination of this Agreement pursuant to this Section 10 shall be without liability on the part of the Company, except that the

Company will continue to be liable for the payment of expenses as set forth in Section 11 hereof and except that the provisions of

Section 7 hereof shall not terminate and shall remain in effect.

(d)            Nothing

contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any non-defaulting Underwriter

for damages caused by its default.

11.            Payment

of Expenses.

(a)            Whether

or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause

to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i) the

costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any taxes payable in that connection;

(ii) the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary

Prospectus, any Issuer Free Writing Prospectus, any Time of Sale Information and the Prospectus (including any exhibits, amendments and

supplements thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of the Transaction Documents;

(iv) the fees and expenses of the Company’s counsel and independent accountants; (v) the fees and expenses incurred in

connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of

such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including

the related fees and expenses of counsel for the Underwriters); (vi) any fees charged by rating agencies for rating the Securities,

if applicable; (vii) the fees and expenses of the Trustee and any paying agent (including related reasonable fees and expenses of

any counsel to such parties); (viii) all expenses and application fees incurred in connection with any filing with, and clearance

of the offering by, the Financial Industry Regulatory Authority; and (ix) all expenses incurred by the Company in connection with

any “road show” presentation to potential investors.

(b)            If

(i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason fails to tender the Securities

for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Securities for any reason permitted under this

Agreement, the Company agrees to reimburse the Underwriters for all out-of-pocket costs and expenses (including the fees and expenses

of their counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby.

12.            Persons

Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective

successors and the officers and directors and any controlling persons referred to in Section 7 hereof. Nothing in this Agreement

is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement

or any provision contained herein. No purchaser of Securities from any Underwriter shall be deemed to be a successor merely by reason

of such purchase.

13.            Survival.

The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriters contained

in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant

hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination

of this Agreement or any investigation made by or on behalf of the Company or the Underwriters.

14.            Recognition

of the U.S. Special Resolution Regimes. In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding

under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under

this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this

Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

In the event that any Underwriter

that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime,

Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent

than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the

United States or a state of the United States.

For the purposes of this Section 14:

“BHC Act Affiliate”

has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k);

“Covered Entity”

means any of the following:

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R.

§ 252.82(b);

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R.

§ 47.3(b); or

(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R.

§ 382.2(b);

“Default Right” has

the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable;

and

“U.S. Special Resolution

Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title

II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

15.            Certain

Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate”

has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means

any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term “subsidiary”

has the meaning set forth in Rule 405 under the Securities Act.

16.            Miscellaneous.

(a)            Authority

of the Representatives. Any action by the Underwriters hereunder may be taken by Barclays, BofA or Citi on behalf of the Underwriters,

and any such action taken by Barclays, BofA or Citi shall be binding upon the Underwriters.

(b)            Notices. All

notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted

and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o

Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019 (fax: (646) 834-8133); Attention: Syndicate Registration; BofA

Securities, Inc., 114 West 47th Street, NY8-114-07-01, New York, New York 10036 (fax: (212) 901-7881); Attention: High Grade

Debt Capital Markets Transaction Management/Legal; and Citigroup Global Markets Inc., 388 Greenwich Street, New York,

New York 10013, Attention: General Counsel; with a copy to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, New

York 10020 (fax: (212) 751-4864); Attention: Greg Rodgers. Notices to the Company shall be given to it at 333 Lakeside Drive, Foster

City, California 94404 (fax: (650) 578-9264); Attention: Chief Financial Officer and General Counsel, with a copy to Sidley Austin

LLP, 787 Seventh Avenue, New York, New York 10019; Attention: Robert A. Ryan and Kayla M. West, Email: rryan@sidley.com, kwest@sidley.com.

Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed

in accordance with the laws of the State of New York. The Company agrees that any suit or proceeding

arising in respect of this Agreement or the Underwriters’ engagement will be tried exclusively in the U.S. District Court for the

Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and

County of New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts.

(d)            Waiver

of Trial by Jury. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable

law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated

hereby.

(e)            Counterparts.

This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication),

each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered

via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions

Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart

so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(f)             Amendments

or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall

in any event be effective unless the same shall be in writing and signed by the parties hereto.

(g)            Headings.

The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or

interpretation of, this Agreement.

(h)            Patriot

Act. In accordance with the requirements of the U.S. Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)),

the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company,

which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters

to properly identify their respective clients.

If the foregoing is in accordance

with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.

Very truly yours,

GILEAD SCIENCES, INC.

/s/ Andrew D. Dickinson

Name:

Andrew D. Dickinson

Title:

Executive Vice President and Chief Financial Officer

[Signature Page – Underwriting Agreement]

Accepted as of the date set forth above:

Barclays Capital Inc.

BofA Securities, Inc.

Citigroup Global Markets Inc.

For themselves and on behalf of the

several Underwriters listed

in Schedule 1 hereto.

Barclays Capital Inc.

/s/

James Gutow

Name:  James Gutow

Title: Managing Director, Head of Healthcare & CMG DCM

BofA Securities, Inc.

/s/

Doug Muller

Name: Doug Muller

Title: Managing Director

Citigroup Global Markets Inc.

/s/

Adam D. Bordner

Name: Adam D. Bordner

Title: Managing Director

[Signature Page – Underwriting Agreement]

Schedule 1

Underwriters

Principal

Amount of

2028 Notes

Principal

Amount of

2029 Notes

Principal

Amount of

2031 Notes

Principal

Amount of

2034 Notes

Barclays Capital Inc.

$ 75,000,000

$ 150,000,000

$ 75,000,000

BofA Securities, Inc.

75,000,000

150,000,000

75,000,000

Citigroup Global Markets Inc.

75,000,000

150,000,000

75,000,000

Goldman Sachs & Co. LLC

26,750,000

53,500,000

26,750,000

HSBC Securities (USA) Inc.

26,750,000

53,500,000

26,750,000

J.P. Morgan Securities LLC

26,750,000

53,500,000

26,750,000

Mizuho Securities USA LLC

26,750,000

53,500,000

26,750,000

Morgan Stanley & Co. LLC

26,750,000

53,500,000

26,750,000

RBC Capital Markets, LLC

26,750,000

53,500,000

26,750,000

SG Americas Securities, LLC

26,750,000

53,500,000

26,750,000

TD Securities (USA) LLC

26,750,000

53,500,000

26,750,000

U.S. Bancorp Investments, Inc.

26,750,000

53,500,000

26,750,000

Wells Fargo Securities, LLC

26,750,000

53,500,000

26,750,000

Blaylock Van, LLC

1,500,000

3,000,000

1,500,000

Siebert Williams Shank & Co., LLC

1,500,000

3,000,000

1,500,000

Independence Point Securities LLC

1,500,000

3,000,000

1,500,000

CastleOak Securities, L.P.

1,500,000

3,000,000

1,500,000

Samuel A. Ramirez & Company, Inc.

1,500,000

3,000,000

1,500,000

Total

$ 500,000,000

$ 1,000,000,000

$ 500,000,000

Annex A

a. Time of Sale Information

Term sheets containing the terms of the Securities,

substantially in the form of Annex B.

A-1

Annex B

PRICING TERM SHEETS

See attached

B-1

Free Writing Prospectus

Filed Pursuant to Rule 433

Registration Statement No. 333-273745

May 14, 2026

GILEAD SCIENCES, INC.

PRICING TERM SHEET

4.250% SENIOR NOTES DUE 2028

4.400% SENIOR NOTES DUE 2029

4.600% SENIOR NOTES DUE 2031

4.900% SENIOR NOTES DUE 2034

Issuer:

Gilead Sciences, Inc. (the “Company”)

Title of Security:

4.250% Senior Notes due 2028 (the “2028 Notes”)

4.400% Senior Notes due 2029 (the “2029 Notes”)

4.600% Senior Notes due 2031 (the “2031 Notes”)

4.900% Senior Notes due 2034 (the “2034 Notes”)

Principal Amount:

2028 Notes: $500,000,000

2029 Notes: $1,000,000,000

2031 Notes: $1,000,000,000

2034 Notes: $500,000,000

Trade Date:

May 14, 2026

Settlement Date:

May 20, 2026 (T+4)

It is expected that delivery of the notes will be made against payment therefor on or about May 20, 2026, which is the fourth business day following the date of the pricing of the notes (T+4). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on or after the date of pricing but prior to the closing date may be required, by virtue of the fact that the notes initially will settle in T+4, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisers.

B-2

Maturity Date:

2028 Notes: May 20, 2028

2029 Notes: May 20, 2029

2031 Notes: May 20, 2031

2034 Notes: May 20, 2034

Price to Public:

2028 Notes: 99.958% of the principal amount

2029 Notes: 99.981% of the principal amount

2031 Notes: 99.996% of the principal amount

2034 Notes: 99.987% of the principal amount

Yield to Maturity:

2028 Notes: 4.272%

2029 Notes: 4.407%

2031 Notes: 4.601%

2034 Notes: 4.902%

Spread to Benchmark Treasury:

2028 Notes: 28 basis points

2029 Notes: 38 basis points

2031 Notes: 48 basis points

2034 Notes: 45 basis points

Benchmark Treasury:

2028 Notes: 3.750% due April 30, 2028

2029 Notes: 3.875% due April 15, 2029

2031 Notes: 3.875% due April 30, 2031

2034 Notes: 4.125% due February 15, 2036

Benchmark Treasury Price / Yield:

2028 Notes: 99-17+ / 3.992%

2029 Notes: 99-18 ⅝ / 4.027%

2031 Notes: 98-29 / 4.121%

2034 Notes: 97-13 ¾ / 4.452%

Interest Payment Dates:

2028 Notes: May 20 and November 20, commencing November 20, 2026

2029 Notes: May 20 and November 20, commencing November 20, 2026

2031 Notes: May 20 and November 20, commencing November 20, 2026

2034 Notes: May 20 and November 20, commencing November 20, 2026

Optional Redemption:

Make-Whole Call:

2028 Notes: T+5 basis points, prior to May 20, 2028

2029 Notes: T+10 basis points, prior to April 20, 2029 (assuming the notes called for redemption matured on April 20, 2029)

2031 Notes: T+10 basis points, prior to April 20, 2031 (assuming the notes called for redemption matured on April 20, 2031)

2034 Notes: T+10 basis points, prior to March 20, 2034 (assuming the notes called for redemption matured on March 20, 2034)

B-3

Par Call:

2028 Notes: N/A (Make-Whole Call only)

2029 Notes: At 100%, on or after April 20, 2029

2031 Notes: At 100%, on or after April 20, 2031

2034 Notes: At 100%, on or after March 20, 2034

CUSIP / ISIN:

2028 Notes: 375558 CJ0 / US375558CJ09

2029 Notes: 375558 CK7 / US375558CK71

2031 Notes: 375558 CL5 / US375558CL54

2034 Notes: 375558 CM3 / US375558CM38

Day Count Convention:

360-day year consisting of twelve 30-day months

Joint Book-Running Managers:

Barclays Capital Inc.

BofA Securities, Inc.

Citigroup Global Markets Inc.

Goldman Sachs & Co. LLC

HSBC Securities (USA) Inc.

J.P. Morgan Securities LLC

Mizuho Securities USA LLC

Morgan Stanley & Co. LLC

RBC Capital Markets, LLC

SG Americas Securities, LLC

TD Securities (USA) LLC

U.S. Bancorp Investments, Inc.

Wells Fargo Securities, LLC

Co-Managers:

Blaylock Van, LLC

CastleOak Securities, L.P.

Independence Point Securities LLC

Samuel A. Ramirez & Company, Inc.

Siebert Williams Shank & Co., LLC

*          *          *

The issuer has filed a registration statement (including a prospectus)

and a prospectus supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the

prospectus in that registration statement, the prospectus supplement and other documents the issuer has filed with the SEC for more complete

information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you

request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847, calling BofA Securities, Inc. toll free at 1-800-294-1322

or calling Citigroup Global Markets Inc. toll-free at 1-800-831-9146.

This pricing term sheet supplements the Preliminary Prospectus Supplement

filed by Gilead Sciences, Inc. on May 14, 2026 relating to its Prospectus dated August 4, 2023.

B-4

EX-4.2 — EXHIBIT 4.2

EX-4.2

Filename: tm2615045d1_ex4-2.htm · Sequence: 3

Exhibit

4.2

ELEVENTH SUPPLEMENTAL INDENTURE

GILEAD SCIENCES, INC.

AND

COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION,

AS SUCCESSOR TO

WELLS FARGO BANK, NATIONAL ASSOCIATION, AS

TRUSTEE

Eleventh Supplemental Indenture

Dated as of May 20, 2026

Supplementing the Indenture

Dated as of March 30, 2011

4.250% Senior Notes due 2028

4.400% Senior Notes due 2029

4.600% Senior Notes due

2031

4.900% Senior Notes due

2034

THIS

ELEVENTH SUPPLEMENTAL INDENTURE is entered into as of May 20, 2026 (this “Eleventh Supplemental Indenture”)

by and between Gilead Sciences, Inc., a corporation duly organized and existing under the laws of Delaware (herein called the “Company”),

and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, a national banking association,

as Trustee (herein called the “Trustee”).

RECITALS:

WHEREAS, the Company and the

Trustee have heretofore executed and delivered an Indenture, dated as of March 30, 2011 (as heretofore supplemented, the “Base

Indenture” and, together with this Eleventh Supplemental Indenture, the “Indenture”), providing for the

issuance from time to time of the Company’s debentures, notes or other evidences of indebtedness (herein and therein called the

“Securities”), to be issued in one or more series as provided in the Base Indenture;

WHEREAS, Section 12.1

of the Base Indenture permits the Company and the Trustee to enter into an indenture supplemental to the Base Indenture to establish

the form and terms of any series of Securities;

WHEREAS, Section 2.1 of

the Base Indenture permits the form of Securities of any series to be established in an indenture supplemental to the Base Indenture;

WHEREAS, Section 3.1 of

the Base Indenture permits certain terms of any series of Securities to be established pursuant to an indenture supplemental to the Base

Indenture;

WHEREAS, pursuant to Sections

2.1 and 3.1 of the Base Indenture, the Company desires to provide for the establishment of four new series of Securities under the Base

Indenture, the form and substance of such Securities and the terms, provisions and conditions thereof to be set forth as provided in

the Base Indenture and this Eleventh Supplemental Indenture; and

WHEREAS, all things necessary

to make this Eleventh Supplemental Indenture a valid agreement of the Company, in accordance with its terms, have been done.

NOW, THEREFORE, for and in

consideration of the foregoing and the purchase of the Securities of four new series established by this Eleventh Supplemental Indenture

by the holders thereof (the “Holders”), it is mutually agreed, for the equal and proportionate benefit of all such

Holders, as follows:

ARTICLE 1

DEFINITIONS AND OTHER PROVISIONS OF GENERAL

APPLICATION

Section 1.01          Relation

to Base Indenture. This Eleventh Supplemental Indenture constitutes a part of the Base Indenture (the provisions of which, as

modified by this Eleventh Supplemental Indenture, shall apply to each series of Notes (as defined in Section 3.01(a))) in respect

of such series of Notes but shall not modify, amend or otherwise affect the Base Indenture insofar as it relates to any other series

of Securities or modify, amend or otherwise affect in any manner the terms and conditions of the Securities of any other series.

Section 1.02          Definitions.

For all purposes of this Eleventh Supplemental Indenture, the capitalized terms used herein (i) which are defined in this Section 1.02

have the respective meanings assigned hereto in this Section 1.02 and (ii) which are defined in the Base Indenture (and which

are not defined in this Section 1.02) have the respective meanings assigned thereto in the Base Indenture. For all purposes of this

Eleventh Supplemental Indenture:

(a)            Unless

the context otherwise requires, any reference to an Article or Section refers to an Article or Section, as the case may

be, of this Eleventh Supplemental Indenture;

(b)            The

words “herein,” “hereof” and “hereunder” and words of similar import refer to this Eleventh Supplemental

Indenture as a whole and not to any particular Article, Section or other subdivision; and

are for convenience of reference only and do not affect interpretations.

ARTICLE 2

GENERAL TERMS AND CONDITIONS OF THE 2028

NOTES

Section 2.01          Terms

of the 2028 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a new series of Securities,

the terms of which shall be as follows:

(a)            Designation.

There is hereby authorized and established a new series of Securities under the Base Indenture, known and designated as the “4.250%

Senior Notes due 2028” (the “2028 Notes”) of the Company. This series of 2028 Notes is unlimited in aggregate

principal amount. The initial aggregate principal amount of the 2028 Notes to be issued under this Eleventh Supplemental Indenture shall

be $500,000,000. Any additional amounts of the 2028 Notes to be issued shall be set forth in a Company Order.

(b)            Form and

Denominations. The 2028 Notes will be issued only in fully registered form, and the authorized denominations of the 2028 Notes shall

be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2028 Notes will initially be issued in the form

of one or more Global Securities substantially in the form of Exhibit A attached hereto, with such modifications thereto

as may be approved by the authorized officer executing the same. The 2028 Notes will be denominated in U.S. dollars and payments of principal,

premium, if any, and interest will be made in U.S. dollars.

Date. The Stated Maturity of principal for the 2028 Notes shall be payable in full on May 20, 2028 (the “2028 Notes

Maturity Date”).

(d)            Interest.

Interest payable on any 2028 Notes Interest Payment Date (as defined below), the 2028 Notes Maturity Date or, if applicable, the Redemption

Date (as determined in accordance with Section 4.2 of the Base Indenture), shall be the amount accrued from, and including, the

immediately preceding 2028 Notes Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including

the original issue date of May 20, 2026 if no interest has been paid or duly provided for with respect to the 2028 Notes) to but

excluding such 2028 Notes Interest Payment Date, 2028 Notes Maturity Date or, if applicable, the Redemption Date, as the case may be

(each, a “2028 Notes Interest Period”). The 2028 Notes will bear interest at the rate of 4.250% per year from the

original issue date thereof to the 2028 Notes Maturity Date. Interest on the 2028 Notes shall be payable semi-annually in arrears on

May 20 and November 20 of each year, beginning on November 20, 2026 (each such date, a “2028 Notes Interest Payment

Date”). The amount of interest payable for any semi-annual 2028 Notes Interest Period will be computed on the basis of a 360-day

year consisting of twelve 30-day months. In the event any 2028 Notes Interest Payment Date on or before the 2028 Notes Maturity Date

falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business

Day and no interest shall accrue as a result of such postponement.

In the event the 2028 Notes

Maturity Date or, if applicable, the Redemption Date, falls on a day that is not a Business Day, then the related payments of principal,

premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate

on the amount payable for the period from and after the 2028 Notes Maturity Date or Redemption Date, as applicable, for such 2028 Note).

Interest due on the 2028 Notes Maturity Date or, if applicable, the Redemption Date, in each case (whether or not a 2028 Notes Interest

Payment Date) will be paid to the Person to whom principal of such 2028 Notes is payable, subject to DTC’s applicable procedures.

(e)            Sinking

Fund; Holder Repurchase Right. The 2028 Notes shall not be subject to any sinking fund or analogous provision or be redeemable at

the option of the Holders.

(f)             Forms.

The 2028 Notes shall be substantially in the form of Exhibit A attached hereto, with such modifications thereto as may be

approved by the authorized officer executing the same.

(g)            Appointment

of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2028 Notes.

(h)            Defeasance.

Until the 2028 Notes Maturity Date, the 2028 Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture.

(i)             Further

Issues. The Company may from time to time, without the consent of the Holders of 2028 Notes, issue additional 2028 Notes. Any such

additional 2028 Notes will have the same ranking, interest rate, maturity date and other terms as the 2028 Notes. Any such additional

2028 Notes, together with the 2028 Notes herein provided for, will constitute a single series of Securities under the Indenture.

ARTICLE 3

GENERAL TERMS AND CONDITIONS OF THE 2029

NOTES

Section 3.01          Terms

of the 2029 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a new series of Securities,

the terms of which shall be as follows:

(a)            Designation.

There is hereby authorized and established a new series of Securities under the Base Indenture, known and designated as the “4.400%

Senior Notes due 2029” (the “2029 Notes”) of the Company. This series of 2029 Notes is unlimited in aggregate

principal amount. The initial aggregate principal amount of the 2029 Notes to be issued under this Eleventh Supplemental Indenture shall

be $1,000,000,000. Any additional amounts of the 2029 Notes to be issued shall be set forth in a Company Order.

(b)            Form and

Denominations. The 2029 Notes will be issued only in fully registered form, and the authorized denominations of the 2029 Notes shall

be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2029 Notes will initially be issued in the form

of one or more Global Securities substantially in the form of Exhibit B attached hereto, with such modifications thereto

as may be approved by the authorized officer executing the same. The 2029 Notes will be denominated in U.S. dollars and payments of principal,

premium, if any, and interest will be made in U.S. dollars.

Date. The Stated Maturity of principal for the 2029 Notes shall be payable in full on May 20, 2029 (the “2029 Notes

Maturity Date”).

(d)            Interest.

Interest payable on any 2029 Notes Interest Payment Date (as defined below), the 2029 Notes Maturity Date or, if applicable, the Redemption

Date (as determined in accordance with Section 4.2 of the Base Indenture), shall be the amount accrued from, and including, the

immediately preceding 2029 Notes Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including

the original issue date of May 20, 2026 if no interest has been paid or duly provided for with respect to the 2029 Notes) to but

excluding such 2029 Notes Interest Payment Date, 2029 Notes Maturity Date or, if applicable, the Redemption Date, as the case may be

(each, a “2029 Notes Interest Period”). The 2029 Notes will bear interest at the rate of 4.400% per year from the

original issue date thereof to the 2029 Notes Maturity Date. Interest on the 2029 Notes shall be payable semi-annually in arrears on

May 20 and November 20 of each year, beginning on November 20, 2026 (each such date, a “2029 Notes Interest Payment

Date”). The amount of interest payable for any semi-annual 2029 Notes Interest Period will be computed on the basis of a 360-day

year consisting of twelve 30-day months. In the event any 2029 Notes Interest Payment Date on or before the 2029 Notes Maturity Date

falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business

Day and no interest shall accrue as a result of such postponement.

In the event the 2029 Notes

Maturity Date or, if applicable, the Redemption Date, falls on a day that is not a Business Day, then the related payments of principal,

premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate

on the amount payable for the period from and after the 2029 Notes Maturity Date or Redemption Date, as applicable, for such 2029 Note).

Interest due on the 2029 Notes Maturity Date or, if applicable, the Redemption Date, in each case (whether or not a 2029 Notes Interest

Payment Date) will be paid to the Person to whom principal of such 2029 Notes is payable, subject to DTC’s applicable procedures.

(e)            Sinking

Fund; Holder Repurchase Right. The 2029 Notes shall not be subject to any sinking fund or analogous provision or be redeemable at

the option of the Holders.

(f)             Forms.

The 2029 Notes shall be substantially in the form of Exhibit B attached hereto, with such modifications thereto as may be

approved by the authorized officer executing the same.

(g)            Appointment

of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2029 Notes.

(h)            Defeasance.

Until the 2029 Notes Maturity Date, the 2029 Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture.

(i)             Further

Issues. The Company may from time to time, without the consent of the Holders of 2029 Notes, issue additional 2029 Notes. Any such

additional 2029 Notes will have the same ranking, interest rate, maturity date and other terms as the 2029 Notes. Any such additional

2029 Notes, together with the 2029 Notes herein provided for, will constitute a single series of Securities under the Indenture.

ARTICLE 4

GENERAL TERMS AND CONDITIONS OF THE 2031

NOTES

Section 4.01          Terms

of the 2031 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a new series of Securities,

the terms of which shall be as follows:

(a)            Designation.

There is hereby authorized and established a new series of Securities under the Base Indenture, known and designated as the “4.600%

Senior Notes due 2031” (the “2031 Notes”) of the Company. This series of 2031 Notes is unlimited in aggregate

principal amount. The initial aggregate principal amount of the 2031 Notes to be issued under this Eleventh Supplemental Indenture shall

be $1,000,000,000. Any additional amounts of the 2031 Notes to be issued shall be set forth in a Company Order.

(b)            Form and

Denominations. The 2031 Notes will be issued only in fully registered form, and the authorized denominations of the 2031 Notes shall

be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2031 Notes will initially be issued in the form

of one or more Global Securities substantially in the form of Exhibit C attached hereto, with such modifications thereto

as may be approved by the authorized officer executing the same. The 2031 Notes will be denominated in U.S. dollars and payments of principal,

premium, if any, and interest will be made in U.S. dollars.

Date. The Stated Maturity of principal for the 2031 Notes shall be payable in full on May 20, 2031 (the “2031 Notes

Maturity Date”).

(d)            Interest.

Interest payable on any 2031 Notes Interest Payment Date (as defined below), the 2031 Notes Maturity Date or, if applicable, the Redemption

Date (as determined in accordance with Section 4.2 of the Base Indenture), shall be the amount accrued from, and including, the

immediately preceding 2031 Notes Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including

the original issue date of May 20, 2026 if no interest has been paid or duly provided for with respect to the 2031 Notes) to but

excluding such 2031 Notes Interest Payment Date, 2031 Notes Maturity Date or, if applicable, the Redemption Date, as the case may be

(each, a “2031 Notes Interest Period”). The 2031 Notes will bear interest at the rate of 4.600% per year from the

original issue date thereof to the 2031 Notes Maturity Date. Interest on the 2031 Notes shall be payable semi-annually in arrears on

May 20 and November 20 of each year, beginning on November 20, 2026 (each such date, a “2031 Notes Interest Payment

Date”). The amount of interest payable for any semi-annual 2031 Notes Interest Period will be computed on the basis of a 360-day

year consisting of twelve 30-day months. In the event any 2031 Notes Interest Payment Date on or before the 2031 Notes Maturity Date

falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business

Day and no interest shall accrue as a result of such postponement.

In the event the 2031 Notes

Maturity Date or, if applicable, the Redemption Date, falls on a day that is not a Business Day, then the related payments of principal,

premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate

on the amount payable for the period from and after the 2031 Notes Maturity Date or Redemption Date, as applicable, for such 2031 Note).

Interest due on the 2031 Notes Maturity Date or, if applicable, the Redemption Date, in each case (whether or not a 2031 Notes Interest

Payment Date) will be paid to the Person to whom principal of such 2031 Notes is payable, subject to DTC’s applicable procedures.

(e)            Sinking

Fund; Holder Repurchase Right. The 2031 Notes shall not be subject to any sinking fund or analogous provision or be redeemable at

the option of the Holders.

(f)            Forms.

The 2031 Notes shall be substantially in the form of Exhibit C attached hereto, with such modifications thereto as may be

approved by the authorized officer executing the same.

(g)            Appointment

of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2031 Notes.

(h)            Defeasance.

Until the 2031 Notes Maturity Date, the 2031 Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture.

(i)             Further

Issues. The Company may from time to time, without the consent of the Holders of 2031 Notes, issue additional 2031 Notes. Any such

additional 2031 Notes will have the same ranking, interest rate, maturity date and other terms as the 2031 Notes. Any such additional

2031 Notes, together with the 2031 Notes herein provided for, will constitute a single series of Securities under the Indenture.

ARTICLE 5

GENERAL TERMS AND CONDITIONS OF THE 2034

NOTES

Section 5.01          Terms

of the 2034 Notes. Pursuant to Sections 2.1 and 3.1 of the Base Indenture, there is hereby established a new series of Securities,

the terms of which shall be as follows:

(a)            Designation.

There is hereby authorized and established a new series of Securities under the Base Indenture, known and designated as the “4.900%

Senior Notes due 2034” (the “2034 Notes” and, together with the 2028 Notes, the 2029 Notes and the 2031

Notes, the “Notes”) of the Company. This series of 2034 Notes is unlimited in aggregate principal amount. The initial

aggregate principal amount of the 2034 Notes to be issued under this Eleventh Supplemental Indenture shall be $500,000,000. Any additional

amounts of the 2034 Notes to be issued shall be set forth in a Company Order.

(b)            Form and

Denominations. The 2034 Notes will be issued only in fully registered form, and the authorized denominations of the 2034 Notes shall

be $2,000 principal amount and any integral multiple of $1,000 in excess thereof. The 2034 Notes will initially be issued in the form

of one or more Global Securities substantially in the form of Exhibit D attached hereto, with such modifications thereto

as may be approved by the authorized officer executing the same. The 2034 Notes will be denominated in U.S. dollars and payments of principal,

premium, if any, and interest will be made in U.S. dollars.

Date. The Stated Maturity of principal for the 2034 Notes shall be payable in full on May 20, 2034 (the “2034 Notes

Maturity Date”).

(d)            Interest.

Interest payable on any 2034 Notes Interest Payment Date (as defined below), the 2034 Notes Maturity Date or, if applicable, the Redemption

Date (as determined in accordance with Section 4.2 of the Base Indenture), shall be the amount accrued from, and including, the

immediately preceding 2034 Notes Interest Payment Date in respect of which interest has been paid or duly provided for (or from and including

the original issue date of May 20, 2026 if no interest has been paid or duly provided for with respect to the 2034 Notes) to but

excluding such 2034 Notes Interest Payment Date, 2034 Notes Maturity Date or, if applicable, the Redemption Date, as the case may be

(each, a “2034 Notes Interest Period”). The 2034 Notes will bear interest at the rate of 4.900% per year from the

original issue date thereof to the 2034 Notes Maturity Date. Interest on the 2034 Notes shall be payable semi-annually in arrears on

May 20 and November 20 of each year, beginning on November 20, 2026 (each such date, a “2034 Notes Interest Payment

Date”). The amount of interest payable for any semi-annual 2034 Notes Interest Period will be computed on the basis of a 360-day

year consisting of twelve 30-day months. In the event any 2034 Notes Interest Payment Date on or before the 2034 Notes Maturity Date

falls on a day that is not a Business Day, the interest payment due on that date will be postponed to the next day that is a Business

Day and no interest shall accrue as a result of such postponement.

In the event the 2034 Notes

Maturity Date or, if applicable, the Redemption Date, falls on a day that is not a Business Day, then the related payments of principal,

premium, if any, and interest may be made on the next succeeding date that is a Business Day (and no additional interest will accumulate

on the amount payable for the period from and after the 2034 Notes Maturity Date or Redemption Date, as applicable, for such 2034 Note).

Interest due on the 2034 Notes Maturity Date or, if applicable, the Redemption Date, in each case (whether or not a 2034 Notes Interest

Payment Date) will be paid to the Person to whom principal of such 2034 Notes is payable, subject to DTC’s applicable procedures.

(e)            Sinking

Fund; Holder Repurchase Right. The 2034 Notes shall not be subject to any sinking fund or analogous provision or be redeemable at

the option of the Holders.

(f)             Forms.

The 2034 Notes shall be substantially in the form of Exhibit D attached hereto, with such modifications thereto as may be

approved by the authorized officer executing the same.

(g)            Appointment

of Agent. The Trustee will initially be the Registrar and Paying Agent with respect to the 2034 Notes.

(h)            Defeasance.

Until the 2034 Notes Maturity Date, the 2034 Notes will be subject to Sections 11.2 and 11.3 of the Base Indenture.

(i)             Further

Issues. The Company may from time to time, without the consent of the Holders of 2034 Notes, issue additional 2034 Notes. Any such

additional 2034 Notes will have the same ranking, interest rate, maturity date and other terms as the 2034 Notes. Any such additional

2034 Notes, together with the 2034 Notes herein provided for, will constitute a single series of Securities under the Indenture.

ARTICLE 6

COVENANTS

Section 6.01          Limitations

on Liens. The restriction set forth in Section 5.2 of the Base Indenture with respect to each series of Notes shall not

apply to, in addition to those otherwise set forth in Section 5.2 of the Base Indenture, the following: Leases, licenses, subleases

or sublicenses of assets (including with respect to real property and intellectual property rights) granted to others that do not in

the aggregate materially interfere with the ordinary conduct of the business of the Company and its Subsidiaries taken as a whole.

Section 6.02          Limitations

on Sale and Leaseback Transactions. Section 5.3(iii) of the Base Indenture is eliminated in its entirety and replaced,

solely insofar as it relates to the Securities issued pursuant to this Eleventh Supplemental Indenture on and after the date of this

Eleventh Supplemental Indenture, with the following:

“(iii) The Corporation or

any Restricted Subsidiary, during the 360 days following the effective date of the Sale and Leaseback Transaction, applies an amount

equal to the greater of the net proceeds of such sale or transfer or the fair value of the Restricted Property that the Corporation or

our Restricted Subsidiary lease in the transaction to (x) the voluntary retirement of the debt securities or other Debt of the Corporation

or that of any Restricted Subsidiary, provided that such Debt (A) ranks pari passu or senior to the Securities and

(B) has a stated maturity which

is either more than 12 months from the date of such application or which is extendable or renewable at the option of the obligor thereon

to a date more than 12 months from the date of such application or (y) the purchase, construction or development of a Restricted

Property.”

Section 6.03          Exempted

Liens and Sale and Leaseback Transactions. Section 5.4 of the Base Indenture is eliminated in its entirety and replaced,

solely insofar as it relates to the Securities issued pursuant to this Eleventh Supplemental Indenture on and after the date of this

Eleventh Supplemental Indenture, with the following:

“Section 5.4 Exempted Liens

and Sale and Leaseback Transactions. Notwithstanding the restrictions described in Sections 5.2 and 5.3 above, the Corporation or

any Restricted Subsidiary may create or assume any Liens not otherwise permitted under Section 5.2 or enter into any Sale and Leaseback

Transactions not otherwise permitted under Section 5.3, if the sum of the following does not exceed 20% of Consolidated Net Tangible

Assets:

(i)             the

outstanding Indebtedness secured by such Liens (not including any Liens permitted under Section 5.2 above which amount does not

include any Liens permitted under the provisions of this Section 5.4); plus

(ii)            all

Attributable Debt in respect of such Sale and Leaseback Transactions entered into (not including any Sale and Leaseback Transactions

permitted under Section 5.3 which amount does not include any Sale and Leaseback Transactions permitted under the provisions of

this Section 5.4), measured, in each case, at the time such Lien is incurred or any such Sale and Leaseback Transaction is entered

into by the Corporation or such Restricted Subsidiary.”

ARTICLE 7

REDEMPTION OF THE NOTES

Section 7.01          Optional

Redemption by Company. The Notes may be redeemed at the option of the Company on the terms and conditions set forth in the form

of Notes as set forth as Exhibit A, Exhibit B, Exhibit C, or Exhibit D, as applicable.

ARTICLE 8

CHANGE OF CONTROL

Section 8.01          Offer

to Purchase Upon Change of Control Triggering Event. Upon the occurrence of a Change of Control Triggering Event (as defined

in the form of Note set forth as Exhibit A, Exhibit B, Exhibit C, and Exhibit D, as applicable),

except with respect to any series of Notes for which the Company has exercised its option to redeem the Notes of such series in full

pursuant to Section 7.01, the Company shall be required to make an offer to each Holder of the applicable series of Notes to repurchase

all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of that Holder’s applicable series of Notes

on the terms and conditions set forth in the form of Note set forth as Exhibit A, Exhibit B, Exhibit C,

or Exhibit D, as applicable.

ARTICLE 9

MISCELLANEOUS

Section 9.01          Relationship

to Existing Base Indenture. This Eleventh Supplemental Indenture is a supplemental indenture within the meaning of the Base Indenture.

The Base Indenture, as supplemented and amended by this Eleventh Supplemental Indenture, is in all respects ratified, confirmed and approved

and, with respect to each series of Notes, the Base Indenture, as supplemented and amended by this Eleventh Supplemental Indenture, shall

be read, taken and construed as one and the same instrument.

Section 9.02          Modification

of the Existing Base Indenture. Except as expressly modified by this Eleventh Supplemental Indenture, the provisions of the Base

Indenture shall govern the terms and conditions of each series of Notes.

Section 9.03          Governing

Law. This Eleventh Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New

York.

Section 9.04          Counterparts.

This Eleventh Supplemental Indenture may be executed in any number of counterparts, each of which when so executed shall be deemed to

be an original, but all such counterparts shall together constitute but one and the same instrument. This Eleventh Supplemental Indenture

(or to any document executed in connection with this supplemental indenture, excluding the notes) shall be valid, binding, and enforceable

against a party only when executed and delivered by an authorized individual on behalf of the party by means of (i) any electronic

signature permitted by the federal Electronic Signatures in Global and National Commerce Act, state enactments of the Uniform Electronic

Transactions Act, and/or any other relevant electronic signatures law, including relevant provisions of the Uniform Commercial Code (collectively,

“Signature Law”); (ii) an original manual signature; or (iii) a faxed, scanned, or photocopied manual signature.

Each electronic signature or faxed, scanned, or photocopied manual signature shall for all purposes have the same validity, legal effect,

and admissibility in evidence as an original manual signature. Each party hereto shall be entitled to conclusively rely upon, and shall

have no liability with respect to, any faxed, scanned, or photocopied manual signature, or other electronic signature, of any party and

shall have no duty to investigate, confirm or otherwise verify the validity or authenticity thereof. The exchange of copies of this Eleventh

Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery

of this Eleventh Supplemental Indenture as to the parties hereto and may be used in lieu of the original Eleventh Supplemental Indenture

for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for

all purposes.

Section 9.05          Trustee

Makes No Representation. The recitals contained herein are made by the Company and not by the Trustee, and the Trustee assumes

no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this Eleventh

Supplemental Indenture (except for its execution thereof and its certificates of authentication of any series of Notes).

Section 9.06           Separability.

In case any provision in the Base Indenture, this Eleventh Supplemental Indenture or any series of Notes shall for any reason be held

to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions shall not in any way be

affected or impaired thereby.

[Signature page follows]

WITNESS WHEREOF, the parties hereto have caused this Eleventh Supplemental Indenture to be duly executed and attested

all as of the day and year first above written.

Date:

GILEAD SCIENCES, INC.

as Issuer

By: /s/ Andrew D. Dickinson

Name: Andrew D. Dickinson

Title: Executive Vice President and Chief Financial Officer

COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION,

as Trustee

By: /s/ Corey J. Dahlstrand

Name: Corey J. Dahlstrand

Title: Vice President

[Signature Page to

Eleventh Supplemental Indenture]

EXHIBIT A

A-1

FORM OF 2028 NOTE

THIS SECURITY IS A GLOBAL SECURITY

WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF THE DEPOSITARY

WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS

SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN

PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED

CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

UNLESS THIS CERTIFICATE IS

PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE

ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE &

CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO

SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE

BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

GILEAD SCIENCES, INC.

No. ___

CUSIP

NO. 375558 CJ0

$_________________

Interest.

Gilead Sciences, Inc., a corporation duly incorporated and existing under the laws of the State of Delaware (herein called the “Company”,

which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to

Cede & Co., or registered assigns, the principal sum of       DOLLARS

($       ), as revised by the Schedule of Increases

or Decreases in Global Security attached hereto, on May 20, 2028 and to pay interest thereon from May 20, 2026 or from the

most recent 2028 Notes Interest Payment Date to which interest has been paid or duly provided for, semi-annually on May 20 and November 20,

in each year, commencing November 20, 2026 at the interest rate of 4.250% per annum, until the principal hereof is paid or made

available for payment. The amount of interest payable for any semi-annual period will be computed on the basis of a 360-day year consisting

of twelve 30-day months.

Method

of Payment. The interest so payable, and punctually paid or duly provided for, on any 2028 Notes Interest Payment Date will,

as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered

at the close of business on the Regular Record Date for such interest, which shall be the May 5 or November 5 (whether or not

a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided

for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this

Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such

Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10

days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any

securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all

as more fully provided in said Indenture.

A-2

Payment of the principal of

(and premium, if any) and interest on this Security will be made at the office or agency of the Trustee maintained for that purpose in

the continental United States, in such coin or currency of the United States of America as at the time of payment is legal tender for

payment of public and private debts.

Reference is hereby made to

the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same

effect as if set forth at this place.

Authentication.

Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature,

this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

A-3

WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

GILEAD SCIENCES, INC.

By:

Name:

Title:

[Global

2028 Note]

A-4

[FORM OF CERTIFICATION OF AUTHENTICATION]

CERTIFICATE OF AUTHENTICATION

This is one of the Securities

of the series designated therein referred to in the within- mentioned Indenture.

Date of

authentication:

COMPUTERSHARE

TRUST COMPANY,

NATIONAL ASSOCIATION,

as Trustee

By:

Authorized Signatory

A-5

[FORM OF REVERSE OF

2028 NOTE]

Indenture.

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued

and to be issued in one or more series under an Indenture, dated as of March 30, 2011 (as heretofore supplemented, herein called

the “Base Indenture”, which term shall have the meaning assigned to it in such instrument), as supplemented by an

Eleventh Supplemental Indenture dated as of May 20, 2026 (herein called the “Eleventh Supplemental Indenture”,

and together with the Base Indenture, the “Indenture”), between the Company and Computershare Trust Company, National

Association, as successor to Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which

term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective

rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of

the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on

the face hereof, initially limited in aggregate principal amount to $500,000,000. The Company may at any time issue additional securities

under the Indenture in unlimited amounts having the same terms as the Securities.

Optional

Redemption. The Securities of this series are subject to redemption at the Company’s option, at any time and from time

to time, in whole or in part, upon not less than 10 nor more than 60 days’ notice mailed or electronically delivered (or otherwise

transmitted in accordance with the depositary’s procedures) to each Holder of Securities to be redeemed at his address as it appears

in the records of the Registrar, on any date prior to their Stated Maturity at a Redemption Price (expressed as a percentage of principal

amount and rounded to three decimal places) equal to the greater of (i) (a) the sum of the present values of the remaining

scheduled payments of principal and interest thereon discounted to the Redemption Date (assuming the Securities matured on their Stated

Maturity) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below)

plus 5 basis points, less (b) interest accrued to the Redemption Date; and (ii) 100% of the principal amount of the Securities

to be redeemed; plus, in either case, accrued and unpaid interest thereon to the Redemption Date (the “Redemption Price”).

The 2028 Notes are not subject

to redemption at par prior to their Stated Maturity and are only redeemable pursuant to the optional redemption described above.

For purposes of determining

the Redemption Price, the following definition is applicable: “Treasury Rate” means, with respect to any Redemption

Date, the yield determined by the Company in accordance with the following two paragraphs.

The Treasury Rate shall be

determined by the Company after 4:15 p.m., New York City time (or after such time as yields on U.S. government securities are posted

daily by the Board of Governors of the Federal Reserve System), on the third Business Day preceding the Redemption Date based upon the

yield or yields for the most recent day that appear after such time on such day in the most recent statistical release published by the

Board of Governors of the Federal Reserve System designated as “Selected Interest Rates (Daily) - H.15” (or any successor

designation or publication) (“H.15”) under the caption “U.S. government securities–Treasury constant maturities–Nominal”

(or any successor caption or heading) (“H.15 TCM”). In determining the Treasury Rate, the Company shall select, as applicable:

(1) the yield for the Treasury constant maturity on H.15 exactly equal to the period from the Redemption Date to the 2028 Notes’

Stated Maturity (the “Remaining Life”); or (2) if there is no such Treasury constant maturity on H.15 exactly equal

to the Remaining Life, the two yields – one yield corresponding to the Treasury constant maturity on H.15 immediately shorter than

and one yield corresponding to the Treasury constant maturity on H.15 immediately longer than the Remaining Life – and shall interpolate

to the 2028 Notes’ Stated Maturity on a straight-line basis (using the actual number of days) using such yields and rounding the

result to three decimal places; or (3) if there is no such Treasury constant maturity on H.15 shorter than or longer than the Remaining

Life, the yield for the single Treasury constant maturity on H.15 closest to the Remaining Life. For purposes of this paragraph, the

applicable Treasury constant maturity or maturities on H.15 shall be deemed to have a maturity date equal to the relevant number of months

or years, as applicable, of such Treasury constant maturity from the Redemption Date.

A-6

If on the third Business Day

preceding the Redemption Date H.15 TCM is no longer published, the Company shall calculate the Treasury Rate based on the rate per annum

equal to the semi-annual equivalent yield to maturity at 11:00 a.m., New York City time, on the second Business Day preceding such Redemption

Date of the United States Treasury security maturing on, or with a maturity that is closest to, the 2028 Notes’ Stated Maturity,

as applicable. If there is no United States Treasury security maturing on the 2028 Notes’ Stated Maturity but there are two or

more United States Treasury securities with a maturity date equally distant from the 2028 Notes’ Stated Maturity, one with a maturity

date preceding the 2028 Notes’ Stated Maturity and one with a maturity date following the 2028 Notes’ Stated Maturity, the

Company shall select the United States Treasury security with a maturity date preceding the 2028 Notes’ Stated Maturity. If there

are two or more United States Treasury securities maturing on the 2028 Notes’ Stated Maturity or two or more United States Treasury

securities meeting the criteria of the preceding sentence, the Company shall select from among these two or more United States Treasury

securities the United States Treasury security that is trading closest to par based upon the average of the bid and asked prices for

such United States Treasury securities at 11:00 a.m., New York City time. In determining the Treasury Rate in accordance with the terms

of this paragraph, the semi-annual yield to maturity of the applicable United States Treasury security shall be based upon the average

of the bid and asked prices (expressed as a percentage of principal amount) at 11:00 a.m., New York City time, of such United States

Treasury security, and rounded to three decimal places.

The Company’s actions

and determinations in determining the Redemption Price shall be conclusive and binding for all purposes, absent manifest error.

In the case of a partial redemption,

selection of the Securities for redemption will be made pro rata, by lot or by such other method as the Trustee deems appropriate and

fair. No Securities of a principal amount of $2,000 or less will be redeemed in part. If any Security is to be redeemed in part only,

the notice of redemption that relates to the Security will state the portion of the principal amount of the Security to be redeemed.

A new Security in a principal amount equal to the unredeemed portion of the Security will be issued in the name of the holder of the

Security upon surrender for cancellation of the original Security. For so long as the Securities are held by DTC (or another depositary),

the redemption of the Securities shall be done in accordance with the policies and procedures of the depositary.

A-7

Unless the Company defaults

in payment of the Redemption Price, on and after the Redemption Date interest will cease to accrue on the Securities or portions thereof

called for redemption.

In the event of redemption

of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be

issued in the name of the Holder hereof upon the cancellation hereof.

Change

of Control. If a Change of Control Triggering Event occurs, unless the Company has exercised its right to redeem the Securities

as described in “Optional Redemption” above, the Company will be required to make an offer to repurchase all, or any part

(equal to $2,000 or an integral multiple of $1,000 in excess thereof), of each Holder’s Securities pursuant to the offer described

below (the “Change of Control Offer”) on the terms set forth herein. In the Change of Control Offer, the Company will

be required to offer payment in cash equal to 101% of the aggregate principal amount of Securities repurchased plus accrued and unpaid

interest, if any, on the Securities repurchased, to the date of repurchase (the “Change of Control Payment”), subject

to the rights of Holders of Securities on the relevant record date to receive interest due on the relevant Interest Payment Date.

Within 30 days following any

Change of Control Triggering Event or, at the Company’s option, prior to any Change of Control but after the public announcement

of the pending Change of Control, the Company will be required to send, or cause the Trustee to send on the Company’s behalf and

at the Company’s sole expense, by first class mail or in accordance with applicable depositary procedures, a notice to Holders

of Securities describing the transaction or transactions that constitute or may constitute the Change of Control Triggering Event and

offering to repurchase the Securities on the date specified in the notice, which date will be no earlier than 30 days and no later than

60 days from the date such notice is sent (the “Change of Control Payment Date”), pursuant to the procedures required

herein and described in such notice. The Company must comply with the requirements of Rule 14e-1 under the Securities Exchange Act

of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those

laws and regulations are applicable in connection with the repurchase of the Securities as a result of a Change of Control Triggering

Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of Control provisions herein,

the Company will be required to comply with the applicable securities laws and regulations and will not be deemed to have breached its

obligations under the Change of Control provisions herein by virtue of such conflicts.

On the Change of Control Payment

Date, the Company will be required, to the extent lawful, to:

(a)            accept

for payment all Securities or portions of Securities properly tendered, and not validly withdrawn, pursuant to the Change of Control

Offer;

(b)            no

later than 11:00 a.m. New York City time, deposit with the Paying Agent an amount equal to the Change of Control Payment in respect

of all Securities or portions of Securities properly tendered and not validly withdrawn; and

A-8

or cause to be delivered to the Trustee the Securities properly accepted together with an Officers’ Certificate stating the aggregate

principal amount of Securities or portions of Securities being purchased by the Company.

The Paying Agent will be required

to send promptly to each Holder who properly tendered Securities the purchase price for such Securities and the Trustee will be required

to authenticate and send (or cause to be transferred by book entry) promptly to each such Holder a new Security equal in principal amount

to any unpurchased portion of the Securities surrendered, if any, provided that each new Security will be in a principal amount

of $2,000 or an integral multiple of $1,000 in excess thereof.

Notwithstanding the foregoing,

the Company will not be required to make a Change of Control Offer with respect to the Securities upon the occurrence of a Change of

Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements

for such an offer made by the Company and the third party purchases all such Securities properly tendered and not validly withdrawn under

its offer. Further, the Company will not be required to repurchase any Securities if there has occurred and is continuing on the Change

of Control Payment Date an Event of Default.

If Holders of not less than

90% in aggregate principal amount of the outstanding Notes of any series validly tender and do not withdraw such notes in a Change of

Control Offer and the Company, or any third party making such an offer in lieu of the Company as described above, purchases all of such

notes validly tendered and not withdrawn by such Holders, the Company or such third party will have the right, upon not less than 30

days nor more than 60 days’ prior notice, provided that such notice is given not more than 30 days following such repurchase pursuant

to the Change of Control Offer described above, to redeem all Notes of such series that remain outstanding following such purchase on

a date specified in such notice (the “Second Change of Control Payment Date”) and at a price in cash equal to 101% of the

aggregate principal amount of the notes repurchased plus any accrued and unpaid interest on the Notes repurchased to, but not including,

the Second Change of Control Payment Date.

For purposes of the foregoing

discussion of a repurchase at the option of Holders, the following definitions are applicable:

“Capital Stock”

means the capital stock of every class whether now or hereafter authorized, regardless of whether such capital stock shall be limited

to a fixed sum or percentage with respect to the rights of the holders thereof to participate in dividends and in the distribution of

assets upon the voluntary or involuntary liquidation, dissolution or winding up of such corporation.

“Change of Control”

means the occurrence of any of the following:

(a)            the

direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more

series of related transactions, of all or substantially all of the Company’s assets and the assets of its Subsidiaries, taken as

a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than the Company

or one of its Subsidiaries;

A-9

(b)            the

consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person”

(as that term is used in Section 13(d)(3) of the Exchange Act) other than the Company or one of its Subsidiaries, becomes the

“beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than 50% of the

Company’s then outstanding Voting Stock or other Voting Stock into which the Company’s Voting Stock is reclassified, consolidated,

exchanged or changed, measured by voting power rather than number of shares;

Company consolidates, or merges with or into any person, or any person consolidates with, or merges with or into, the Company, in any

such event pursuant to a transaction in which any of its Voting Stock or the Voting Stock of such other person is converted into or exchanged

for cash, securities or other property, other than any such transaction where the shares of the Company’s Voting Stock outstanding

immediately prior to such transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving

person or any direct or indirect parent company of the surviving person immediately after giving effect to such transaction; or

(d)            the

adoption of a plan relating to the Company’s liquidation or dissolution.

Notwithstanding paragraphs

(a), (b) and (c) above, a transaction will not be considered to be a Change of Control if (a) the Company becomes a direct

or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect

holders of the Voting Stock of the holding company are substantially the same as the holders of the Company’s Voting Stock immediately

prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly,

of more than 50% of the Voting Stock of such holding company.

“Change of Control

Triggering Event” means the occurrence of both a Change of Control and a Rating Event. Notwithstanding anything herein to the

contrary, no Change of Control Triggering Event will be deemed to have occurred in connection with (i) any particular Change of

Control unless and until such Change of Control has actually been consummated or (ii) any reduction in rating if the Rating Agencies

making the reduction in rating to which this definition would otherwise apply do not announce or publicly confirm or inform the Trustee

in writing at its request that the reduction was the result of any event or circumstance comprised of or arising as a result of, or in

respect of, a Change of Control (whether or not the Change of Control shall have occurred at the time of the reduction in rating).

“Investment Grade”

means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating categories of Moody’s) and a rating

of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) or the equivalent investment grade

credit rating from any additional Rating Agency or Rating Agencies selected by the Company in accordance with the definition of “Rating

Agencies.”

“Moody’s”

means Moody’s Investors Service, Inc., a subsidiary of Moody’s Corporation, and its successors.

A-10

“Rating Agencies”

means (a) each of Moody’s and S&P; and (b) if any of Moody’s or S&P ceases to rate the Securities or fails

to make a rating of the Securities publicly available for reasons outside of the Company’s control, a “nationally recognized

statistical rating organization” within the meaning of Section 3(a)(62) of the Exchange Act that is selected by the Company

(as certified by a resolution of the Company’s board of directors) as a replacement agency for Moody’s or S&P, or both

of them, as the case may be.

“Rating Event”

means, with respect to the Securities, the rating on the Securities is lowered below Investment Grade by each of the Rating Agencies

then providing a rating for such Securities on any date beginning on the date of public notice of an arrangement that could result in

a Change of Control until the end of the 60-day period following public notice of the occurrence of the Change of Control (which 60-day

period shall be extended so long as the rating of such Securities is under publicly announced consideration for possible downgrade by

any of the Rating Agencies, such extension to last with respect to each such Rating Agency until the date on which such Rating Agency

considering such possible downgrade either (x) rates such Securities below Investment Grade or (y) publicly announces that

it is no longer considering such Securities for possible downgrade).

“S&P”

means S&P Global Ratings, a division of S&P Global Inc., and its successors.

“Voting Stock”

means, with respect to any specified person as of any date, the Capital Stock of such person that is at the time entitled to vote generally

in the election of the board of directors of such person.

The Indenture contains provisions

for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect

to this Security, in each case upon compliance with certain conditions set forth in the Indenture, which provisions apply to this Security.

This Security is not subject to repayment at the Holder’s option.

No reference herein to the

Indenture and no provision of this Security or the Indenture shall affect or impair the obligation of the Company, which is absolute

and unconditional, to pay the principal of, premium, if any, and interest on this Security at the respective due dates, place and rate,

and in the Currency herein prescribed.

Default

and Remedies. If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal

of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.

Amendment,

Modification and Waiver. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the

modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected

under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the

Securities at the time outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified

percentages in principal amount of the Securities of each series at the time outstanding, on behalf of the Holders of all Securities

of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture

and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and

upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or

in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

A-11

Denominations;

Transfer and Exchange. As provided in the Indenture and subject to certain limitations therein set forth, the transfer of

this Security is registrable in the records of the Registrar, upon surrender of this Security for registration of transfer at the office

or agency of the Company in any place where the principal of and any premium and interest on this Security are payable, duly endorsed

by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed by, the Holder

hereof or the Holder’s attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like

tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

The Securities of this series

are issuable only in registered form in denominations of $2,000 and any integral multiple of $1,000 in excess thereof. As provided in

the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal

amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering

the same.

No service charge shall be

made to a Holder for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover

any tax or other governmental charge payable in connection therewith.

Persons

Deemed Owners. Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent

of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether

or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

Miscellaneous.

The Indenture and the Securities, including this Security, shall be governed by and construed in accordance with the laws of the State

of New York.

All terms used in this Security

and not defined herein shall have the meanings assigned to them in the Indenture.

Pursuant to a recommendation

promulgated by the Committee on Uniform Security Identification Procedures, the Company has caused “CUSIP” numbers to be

printed on the Securities as a convenience to the Holders of the Securities. No representation is made as to the correctness or accuracy

of such CUSIP numbers as printed on the Securities, and reliance may be placed only on the other identification numbers printed hereon.

Unless the certificate of authentication

hereon has been executed by or on behalf of the Trustee by manual signature, this Security shall not be entitled to any benefit under

the Indenture or be valid or obligatory for any purpose.

A-12

ASSIGNMENT FORM

FOR VALUE RECEIVED, the undersigned hereby

sells, assigns and transfers unto

PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING

NUMBER OF ASSIGNEE

(Please

Print or Typewrite Name and Address, including Zip Code, of Assignee)

the

within Security of Gilead Sciences, Inc. and ________________ hereby does irrevocably

constitute and appoint

Attorney

to transfer said Security on the books of the within-named Company with full power of substitution in the premises

Dated:

Signature

NOTICE: The signature

to this assignment must correspond with the name as it appears on the first page of the within Security in every particular,

without alteration or enlargement or any change whatever.

Signature

Guaranteed:

NOTICE: Signature(s) must

be guaranteed by an “eligible guarantor institution” that is a member or participant in a “signature

guarantee program” (e.g., the Securities Transfer Agents Medallion Program, the Stock Exchange Medallion Program and the

New York Stock Exchange Medallion Program).

A-13

SCHEDULE OF INCREASES OR DECREASES IN GLOBAL SECURITY

The following increases or decreases in this Global

Security have been made:

Date

of Exchange

Amount of

increase in

Principal Amount

of this Global

Security

Amount of

decrease in

Principal Amount

of this Global

Security

Principal Amount

of this Global

Security following

such decrease or

increase

Signature of

authorized

signatory of

Trustee

A-14

EXHIBIT B

B-1

FORM OF 2029 NOTE

THIS SECURITY IS A GLOBAL SECURITY

WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF THE DEPOSITARY

WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE OR ANY AGENT THEREOF AS OWNER AND HOLDER OF THIS SECURITY FOR ALL PURPOSES. THIS

SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN

PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITARY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED

CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

UNLESS THIS CERTIFICATE IS

PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE

ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE &

CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO

SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE

BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

GILEAD SCIENCES, INC.

No. ___

CUSIP

NO. 375558 CK7

$_________________

Interest.

Gilead Sciences, Inc., a corporation duly incorporated and existing under the laws of the State of Delaware (herein called the “Company”,

which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to

Cede & Co., or registered assigns, the principal sum of       DOLLARS

($       ), as revised by the Schedule of Increases

or Decreases in Global Security attached hereto, on May 20, 2029 and to pay interest thereon from May 20, 2026 or from the

most recent 2029 Notes Interest Payment Date to which interest has been paid or duly provided for, semi-annually on May 20 and November 20,

in each year, commencing November 20, 2026 at the interest rate of 4.400% per annum, until the principal hereof is paid or made

available for payment. The amount of interest payable for any semi-annual period will be computed on the basis of a 360-day year consisting

of twelve 30-day months.

Method

of Payment. The interest so payable, and punctually paid or duly provided for, on any 2029 Notes Interest Payment Date will,